Drug Development Pharma - February 28, 2014
Oasmia gets FDA approval for veterinary drug
The U.S. Food and Drug Administration (FDA) has conditionally approved the Swedish pharmaceutical company’s product Paccal. Paccal Vet-CA1 is the first veterinary drug to utilize paclitaxel, a frequently used chemotherapeutics for the treatment of a wide range of cancers in humans. Paccal Vet-CA1 is specifically formulated for use in dogs for the treatment of canine skin and mammary cancers. […]
Drug Development Pharma - February 28, 2014
Automated dispensing of medicines introduced at Kuopio University Hospital
Etteplan is designing an new medical automation system for Newico for tracking a pharmaceutical product all the way from the factory to the patient. The first part of the system will be introduced at Kuopio University Hospital in Finland in 2015. Kuopio University Hospital has placed an order with Newico for an automation solution for […]
Drug Development Pharma - February 25, 2014
FDA approves Myalept to treat rare metabolic disease
The U.S. Food and Drug Administration has approved AstraZeneca’s and Bristol-Myers Squibb’s Myalept as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. The safety and effectiveness of Myalept, an analog of leptin made through recombinant DNA technology, were evaluated in an open-label, […]
Drug Development Pharma - February 12, 2014
AstraZeneca’s Onglyza on review
The diabetes drug Onglyza is under the FDA’s microscope as the agency said it would review possible heart risks associated with the medication. The decision comes after a study published in the New England Journal of Medicine. The study flagged an increase in heart failure hospitalizations among patients who used Onglyza (saxagliptin). The active ingredient is […]
Drug Development Pharma - February 6, 2014
AstraZeneca cuts another 550 jobs
On February 6 AstraZeneca released its full quarter and full year results 2013 where it stood clear that the company expects another 550 layoffs due to savings. Of the 550 jobs, 168 of them will be cut off as the R&D unit in Avishkar (Bangalore, India) is closed down. The remaining 400 posts will be […]
Drug Development Pharma - February 5, 2014
SMEs drive behind innovative medicine
Over 40% of innovative medicines recommended for marketing authorisation in the European Union between 2010 and 2012 originated from small or medium-sized enterprises, says EMA. According to an article published recently in Nature Reviews Drug Discovery, authored by staff members of the European Medicines. Agency (EMA), small or medium-sized enterprises (SMEs), academia, public bodies and […]
